Surrozen, Inc. (SRZN)
| Market Cap | 355.86M |
| Revenue (ttm) | 3.48M |
| Net Income (ttm) | -242.03M |
| Shares Out | 11.49M |
| EPS (ttm) | -32.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,480 |
| Open | 29.89 |
| Previous Close | 29.95 |
| Day's Range | 29.89 - 31.53 |
| 52-Week Range | 5.90 - 33.96 |
| Beta | 0.52 |
| Analysts | Strong Buy |
| Price Target | 38.00 (+22.66%) |
| Earnings Date | May 8, 2026 |
About SRZN
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular ag... [Read more]
Financial Performance
In 2025, Surrozen's revenue was $3.48 million, a decrease of -67.37% compared to the previous year's $10.66 million. Losses were -$242.03 million, 280.8% more than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for SRZN stock is "Strong Buy." The 12-month stock price target is $38.0, which is an increase of 22.66% from the latest price.
News
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the pow...
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meet...
Surrozen Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing multispecific antibody therapies targeting Wnt, VEGF, and IL-6 pathways for retinal vascular diseases, with SZN-8141 leading and an IND planned for 2026. Manufacturing is at commercial scale, and recent financing supports clinical development. The approach aims for superior retinal drying and leverages growing strategic interest in ophthalmology.
Surrozen to Present at Upcoming Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the powe...
Surrozen Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The discussion highlighted the promise of Wnt pathway-targeted therapies for retinal vascular diseases, with lead molecules advancing toward IND in 2026 and a strong competitive and IP position. Financial health is robust, supported by recent fundraising and partnerships.
Surrozen Transcript: Evercore ISI 8th Annual HealthCONx Conference
Plans include a 2026 IND for a multifunctional ophthalmology antibody targeting DME and wet AMD, with a focus on bispecific and trispecific agents that combine Wnt agonism, VEGF, and IL-6 inhibition. Preclinical data show synergy, and retinal drying is prioritized as the key clinical endpoint.
Surrozen Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing bispecific and trispecific antibody therapies for retinal diseases, leveraging Wnt, VEGF, and IL-6 pathways for additive and potentially synergistic effects. IND filing for the lead program is planned for 2026, with strong financial backing to support development.
Surrozen to Present at Upcoming Healthcare Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively mo...
Surrozen Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Wnt pathway activation is being advanced for retinal diseases, with lead molecules 8141 and 8143 targeting DME and wet AMD. Preclinical data show synergy with VEGF and IL-6 inhibition, and IND filing for 8141 is planned for 2026. Strong IP, recent financing, and competitive readouts from Merck are key near-term factors.
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively mo...
Surrozen Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Innovative bispecific antibodies targeting the Wnt pathway show promise for treating major retinal diseases, with preclinical data indicating superior vessel normalization and potential for improved visual outcomes. Lead candidates are set for clinical entry in 2026.
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively m...
Surrozen Transcript: Cantor Global Healthcare Conference 2025
The discussion highlighted a strategic pivot to ophthalmology, leveraging proprietary Wnt pathway technology and strong IP to develop multitargeted therapies for retinal diseases. Lead assets aim for improved efficacy and durability, supported by robust financing and preclinical data.
Surrozen Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Wnt pathway modulation is driving innovation in ophthalmology, with a robust antibody pipeline targeting major retinal and corneal diseases. Preclinical data show superior efficacy to current therapies, and clinical milestones are anticipated in 2025–2026.
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for...
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incor...
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively mod...
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wn...
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases Announces an oversubscribed financing of ...
Surrozen Transcript: Stifel 2024 Healthcare Conference
Lead asset SZN-043 for severe alcohol-associated hepatitis is advancing through phase I-B trials, showing safety and efficacy signals, with key interim and full data readouts expected in 2025. Ophthalmology pipeline prioritizes Frizzled-4 VEGF, and partnerships and milestones provide financial runway.
Surrozen Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference
The company leverages tissue-specific Wnt pathway modulation for regenerative therapies, with SZN-043 showing early safety and efficacy in severe alcoholic hepatitis and SZN-413 advancing in ophthalmology through a major partnership. Key regulatory and clinical milestones are anticipated in the coming months.
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio of ...
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt...
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wingless/In...
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application...